BTCC / BTCC Square / Global Cryptocurrency /
Amgen Inc. (AMGN) Stock Rises on Strong Q3 Performance and Revenue Growth

Amgen Inc. (AMGN) Stock Rises on Strong Q3 Performance and Revenue Growth

Published:
2025-11-04 22:19:02
7
1
BTCCSquare news:

Amgen Inc. (AMGN) saw its stock price edge higher, closing at $296.70, as investors reacted to robust third-quarter results. Revenue surged 12% year-over-year to $9.6 billion, driven by a 14% volume increase across its product portfolio. Key performers included Repatha® and TEPEZZA®, with the former posting a 40% sales jump.

Operating income climbed 25%, while free cash FLOW reached $4.2 billion—a marked improvement. The company's diversified therapeutic offerings, spanning oncology and inflammation, underscore its market resilience. Amgen projects 2025 revenues between $35.8 billion and $36.6 billion, signaling confidence in sustained growth.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.